Deven Choksey of KRChoksey Invst Managers told CNBC-TV18, "Dr Reddy's Laboratories is one company which would be considered to add into the portfolio. Given the direction that it has set, especially in the areas of biosimilars, I feel that this particular company holds a huge amount of potential going forward. Maybe, in coming two years or so, you will get larger clarity on this particular subject coming from the company's side.""There is a good amount of visibility also on the generic launch, the Abbreviated New Drug Applications (ANDA) that they have in the portfolios. So, to a greater extent, I believe that the stock price is offering an opportunity at lower levels. Certainly, you may not see the euphoric upside which we have seen in the past for many of the pharmaceutical companies, even though they are available at lower valuations," he said."I would think that it would be a time to accumulate some of the good quality stocks in portfolio and stay invested with a horizon of at least three years and above. That would be a more rewarding proposition," he added.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
